1 / 5

RIO LIPIDS Trial: Rimonabant Weight Loss Benefits in Obesity

The RIO LIPIDS Trial presented at ACC Scientific Sessions 2004 highlights the weight loss effects of Rimonabant in abdominal obesity patients with abnormal lipid profiles. The study showed significant weight reduction, improved lipid profiles, and reduced CRP levels with Rimonabant treatment compared to placebo over one year. This research sheds light on potential benefits of using selective cannabinoid type 1 receptor antagonists in managing obesity-related health risks.

troy-lester
Download Presentation

RIO LIPIDS Trial: Rimonabant Weight Loss Benefits in Obesity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RIO LIPIDS Trial Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres

  2. RIO LIPIDS Trial 1,036 patients with abdominal obesity and abnormal lipid profiles Randomized, double-blind, multicenter • Rimonabant • A selective cannabinoid type 1 receptor antagonist • 20 mg • n=346 • Rimonabant • A selective cannabinoid type 1 receptor antagonist • 5 mg • n=345 • Placebo • n=342 Treatment for 1 Year • Endpoints (1 year): • Weight loss 5% of body weight and 10% of body weight • Change in lipid profile Presented at ACC Scientific Sessions 2004

  3. RIO LIPIDS Trial Weight Loss 5% p < 0.001 for high-dose vs placebo Weight Loss 10% p < 0.001 for high-dose vs placebo Presented at ACC Scientific Sessions 2004

  4. RIO LIPIDS Trial Relative Reduction in CRP p=0.007 for rimonabant 20 mg vs placebo • C-reactive protein reduction greater in rimonabant 20 mg arm compared with placebo (from 3.7 to 2.7 mg/l with rimonabant 20 mg vs. 3.6 to 3.2 mg/l with placebo, p=0.007) • HDL increased 23% and triglycerides decreased 15% in rimonabant 20 mg, but no significant difference in LDL levels Presented at ACC Scientific Sessions 2004

  5. RIO LIPIDS Trial • Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo • Additional benefits were observed in HDL and triglyceride levels with rimonabant • Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia • Few pharmacologic agents have been identified as both safe and effective in reducing weight, pointing to the potential importance of the present study • Further evaluation is warranted

More Related